{"id":773156,"date":"2023-07-27T15:13:22","date_gmt":"2023-07-27T19:13:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\/"},"modified":"2023-07-27T15:13:22","modified_gmt":"2023-07-27T19:13:22","slug":"celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\/","title":{"rendered":"Celularity and Vers\u00e9a Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance\u00ae and Biovance\u00ae 3l Ocular For Ophthalmic Applications"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">FLORHAM PARK, N.J. and TAMPA, Fla., July  27, 2023  (GLOBE NEWSWIRE) &#8212; Celularity Inc. (Nasdaq: CELU) (\u201cCelularity\u201d), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, and Vers\u00e9a Ophthalmics, LLC (\u201cVers\u00e9a Ophthalmics\u201d), a Tampa, FL-based company that focuses on providing complete ocular point-of-care diagnostic and therapeutic interventions, today announced that the companies have entered into an exclusive U.S. commercialization agreement in which Vers\u00e9a Ophthalmics will distribute Celularity\u2019s BIOVANCE<sup>\u00ae<\/sup> and BIOVANCE<sup>\u00ae<\/sup> 3L Ocular products to support the treatment of ocular surface disease and ocular surgical applications.<\/p>\n<p>BIOVANCE<sup>\u00ae<\/sup> and BIOVANCE<sup>\u00ae<\/sup> 3L Ocular, which are single-layer and three-layer (3L) allografts, respectively, are intended for use as a biological membrane covering that provides an extracellular matrix. BIOVANCE<sup>\u00ae <\/sup>3L Ocular is acellular and consists of three layers of an amniotic membrane that supports treatment of advanced ocular surface disease. As a barrier membrane, BIOVANCE<sup>\u00ae <\/sup>3L Ocular is intended to protect the underlying tissue and preserve tissue plane boundaries. Applications include corneal and conjunctival-related injuries or defects such as corneal epithelial defects, pterygium repair, fornix reconstruction, and other procedures, all of which are significant opportunities, the companies believe.<\/p>\n<p>The global persistent corneal epithelial defect management market is currently valued at <br \/>$8.5 billion, and is expected to grow at an 18 percent compound annual growth rate (CAGR) through 2033, reaching a valuation of $44.49 billion, according to Future Market Insights.<\/p>\n<p>\u201cWe are excited to partner with Vers\u00e9a Ophthalmics to distribute our BIOVANCE<sup>\u00ae<\/sup> and BIOVANCE<sup>\u00ae<\/sup> 3L Ocular products in the U.S.,\u201d said Robert J. Hariri, M.D., Ph.D., Celularity\u2019s CEO, Chairman and Founder. \u201cVers\u00e9a Ophthalmics has the channel expertise in eye care necessary to reach physicians and to provide patients in need access to our innovative biomaterial technology.\u201d<\/p>\n<p>\u201cAs a corneal specialist by training, I have witnessed the transformative impact innovative tissue-based ocular therapeutic interventions can have for patients both in the clinic and surgically,\u201d said Rob Sambursky, M.D., President, Vers\u00e9a Ophthalmics. \u201cOur commercialization agreement with Celularity allows us to offer a decellularized, ringless, advanced wound healing option to drive forward innovation for ocular surface diseases.\u201d<\/p>\n<p>Terms of the agreement are not disclosed.<\/p>\n<p>\n        <strong>About Vers\u00e9a Ophthalmics, LLC <\/strong>\n      <\/p>\n<p>Vers\u00e9a Ophthalmics, LLC is a division of Vers\u00e9a Health, Inc., a diversified life-science company committed to delivering innovative, high-value diagnostic and therapeutic solutions to improve health care quality and access. It is specialized in the sale and distribution of innovative solutions for the diagnosis, treatment, and management of ocular surface diseases and surgical wound healing. To learn more, visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_1JUqzOXarxBE1JZJ-nttNu1S8Osdr75UCkAkTfCRkcTwf8BBV9potRVxLy3vF-9QyN6PMc1ohSUCp-TvZ8DNKIOH9FgFyrPDBgBEJWxO5lE8yo__nBQMolcpZgvxbCb\" rel=\"nofollow noopener\" target=\"_blank\">www.versea.com\/ophthalmics<\/a><\/p>\n<p>\n        <strong>About Celularity<\/strong>\n      <\/p>\n<p>Celularity Inc. (Nasdaq: CELU) headquartered in Florham Park, N.J., is a biotechnology company leading the next evolution in cellular and regenerative medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using mesenchymal-like adherent stromal cells (MLASCs), T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells targeting indications in autoimmune, infectious and degenerative diseases, and cancer. Celularity also develops, manufactures and commercializes innovative biomaterial products also derived from the postpartum placenta. Celularity believes that by harnessing the placenta\u2019s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.<\/p>\n<p>To learn more, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nuABN1nYxZcZZ4sA6m5rsaDW5j1XCFV4-J736TXX0B9qio8NWPGgMRK7DpaWzkk5k4lo7E3556sYNWQxHUwiPY2PUal5BHiDktQVOebkgGc=\" rel=\"nofollow noopener\" target=\"_blank\">www.celularity.com<br \/><\/a><\/p>\n<p>\n        <strong>Celularity Media Contact:<br \/><\/strong>Paul Graves, Chief Communications Officer<br \/>Celularity Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Es0izG1M921LpfGBgnMgOBDeZ_4gjs_HdAnUgyNlPhZxLaybsPb_nQAU3yeSBe0LxZ3Z4Hfdf4ceJ11I8Ln4MeOvhMJjpUwkMez05jBh4fPlzlV9lGve_y19CNjQVLgz\" rel=\"nofollow noopener\" target=\"_blank\">paul.graves@celularity.com<\/a><\/p>\n<p>\n        <strong>Vers\u00e9a<\/strong><br \/>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Rahim K. Hirji, R. Ph.<br \/>Vers\u00e9a Ophthalmics, LLC<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iDzuMs_U0I3ILTrRBOB02xNrRhNSGOXTyR5o6XVqNuEeO3o6O9wE5VwXbPUn8bdShSShSim6JhbgdAM6l7PrmA==\" rel=\"nofollow noopener\" target=\"_blank\">rahim@versea.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4MTY0OCM1NzExOTUxIzUwMDA3ODMxNQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NDRhYzAxYjAtZWI3Ni00YjJjLWI5NzQtOTg2NmFhZWMxMGNiLTUwMDA3ODMxNQ==\/tiny\/Celularity-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>FLORHAM PARK, N.J. and TAMPA, Fla., July 27, 2023 (GLOBE NEWSWIRE) &#8212; Celularity Inc. (Nasdaq: CELU) (\u201cCelularity\u201d), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, and Vers\u00e9a Ophthalmics, LLC (\u201cVers\u00e9a Ophthalmics\u201d), a Tampa, FL-based company that focuses on providing complete ocular point-of-care diagnostic and therapeutic interventions, today announced that the companies have entered into an exclusive U.S. commercialization agreement in which Vers\u00e9a Ophthalmics will distribute Celularity\u2019s BIOVANCE\u00ae and BIOVANCE\u00ae 3L Ocular products to support the treatment of ocular surface disease and ocular surgical applications. BIOVANCE\u00ae and BIOVANCE\u00ae 3L Ocular, which are single-layer and three-layer (3L) allografts, respectively, are intended for use as a biological membrane covering that provides an extracellular matrix. BIOVANCE\u00ae 3L Ocular is acellular and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Celularity and Vers\u00e9a Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance\u00ae and Biovance\u00ae 3l Ocular For Ophthalmic Applications&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-773156","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Celularity and Vers\u00e9a Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance\u00ae and Biovance\u00ae 3l Ocular For Ophthalmic Applications - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celularity and Vers\u00e9a Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance\u00ae and Biovance\u00ae 3l Ocular For Ophthalmic Applications - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FLORHAM PARK, N.J. and TAMPA, Fla., July 27, 2023 (GLOBE NEWSWIRE) &#8212; Celularity Inc. (Nasdaq: CELU) (\u201cCelularity\u201d), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, and Vers\u00e9a Ophthalmics, LLC (\u201cVers\u00e9a Ophthalmics\u201d), a Tampa, FL-based company that focuses on providing complete ocular point-of-care diagnostic and therapeutic interventions, today announced that the companies have entered into an exclusive U.S. commercialization agreement in which Vers\u00e9a Ophthalmics will distribute Celularity\u2019s BIOVANCE\u00ae and BIOVANCE\u00ae 3L Ocular products to support the treatment of ocular surface disease and ocular surgical applications. BIOVANCE\u00ae and BIOVANCE\u00ae 3L Ocular, which are single-layer and three-layer (3L) allografts, respectively, are intended for use as a biological membrane covering that provides an extracellular matrix. BIOVANCE\u00ae 3L Ocular is acellular and &hellip; Continue reading &quot;Celularity and Vers\u00e9a Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance\u00ae and Biovance\u00ae 3l Ocular For Ophthalmic Applications&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-27T19:13:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4MTY0OCM1NzExOTUxIzUwMDA3ODMxNQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Celularity and Vers\u00e9a Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance\u00ae and Biovance\u00ae 3l Ocular For Ophthalmic Applications\",\"datePublished\":\"2023-07-27T19:13:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\\\/\"},\"wordCount\":593,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4MTY0OCM1NzExOTUxIzUwMDA3ODMxNQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\\\/\",\"name\":\"Celularity and Vers\u00e9a Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance\u00ae and Biovance\u00ae 3l Ocular For Ophthalmic Applications - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4MTY0OCM1NzExOTUxIzUwMDA3ODMxNQ==\",\"datePublished\":\"2023-07-27T19:13:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4MTY0OCM1NzExOTUxIzUwMDA3ODMxNQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4MTY0OCM1NzExOTUxIzUwMDA3ODMxNQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celularity and Vers\u00e9a Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance\u00ae and Biovance\u00ae 3l Ocular For Ophthalmic Applications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Celularity and Vers\u00e9a Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance\u00ae and Biovance\u00ae 3l Ocular For Ophthalmic Applications - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\/","og_locale":"en_US","og_type":"article","og_title":"Celularity and Vers\u00e9a Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance\u00ae and Biovance\u00ae 3l Ocular For Ophthalmic Applications - Market Newsdesk","og_description":"FLORHAM PARK, N.J. and TAMPA, Fla., July 27, 2023 (GLOBE NEWSWIRE) &#8212; Celularity Inc. (Nasdaq: CELU) (\u201cCelularity\u201d), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, and Vers\u00e9a Ophthalmics, LLC (\u201cVers\u00e9a Ophthalmics\u201d), a Tampa, FL-based company that focuses on providing complete ocular point-of-care diagnostic and therapeutic interventions, today announced that the companies have entered into an exclusive U.S. commercialization agreement in which Vers\u00e9a Ophthalmics will distribute Celularity\u2019s BIOVANCE\u00ae and BIOVANCE\u00ae 3L Ocular products to support the treatment of ocular surface disease and ocular surgical applications. BIOVANCE\u00ae and BIOVANCE\u00ae 3L Ocular, which are single-layer and three-layer (3L) allografts, respectively, are intended for use as a biological membrane covering that provides an extracellular matrix. BIOVANCE\u00ae 3L Ocular is acellular and &hellip; Continue reading \"Celularity and Vers\u00e9a Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance\u00ae and Biovance\u00ae 3l Ocular For Ophthalmic Applications\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\/","og_site_name":"Market Newsdesk","article_published_time":"2023-07-27T19:13:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4MTY0OCM1NzExOTUxIzUwMDA3ODMxNQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Celularity and Vers\u00e9a Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance\u00ae and Biovance\u00ae 3l Ocular For Ophthalmic Applications","datePublished":"2023-07-27T19:13:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\/"},"wordCount":593,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4MTY0OCM1NzExOTUxIzUwMDA3ODMxNQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\/","name":"Celularity and Vers\u00e9a Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance\u00ae and Biovance\u00ae 3l Ocular For Ophthalmic Applications - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4MTY0OCM1NzExOTUxIzUwMDA3ODMxNQ==","datePublished":"2023-07-27T19:13:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4MTY0OCM1NzExOTUxIzUwMDA3ODMxNQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4MTY0OCM1NzExOTUxIzUwMDA3ODMxNQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-and-versea-ophthalmics-announce-exclusive-u-s-commercialization-agreement-to-distribute-biovance-and-biovance-3l-ocular-for-ophthalmic-applications\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Celularity and Vers\u00e9a Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance\u00ae and Biovance\u00ae 3l Ocular For Ophthalmic Applications"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/773156","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=773156"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/773156\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=773156"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=773156"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=773156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}